This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Biogaia Ab. Active years: 2020-2022.
Company Filing History:
Years Active: 2020-2022
Title: Eamonn Conolly: Innovator in Gastrointestinal Pain Management
Introduction
Eamonn Conolly is a notable inventor based in Lidingo, Sweden. He has made significant contributions to the field of gastrointestinal pain management through his innovative research and patents. With a total of 2 patents, Conolly's work focuses on identifying agents that can effectively reduce or prevent gastrointestinal pain.
Latest Patents
Conolly's latest patents revolve around the selection of agents modulating gastrointestinal pain. The embodiments of these patents relate to agents that are effective in reducing or preventing gastrointestinal pain in a subject. Specifically, these agents are identified based on their capability to reduce spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation. This innovative approach has the potential to significantly improve the quality of life for individuals suffering from gastrointestinal issues.
Career Highlights
Eamonn Conolly has established himself as a key figure in his field, working with Biogaia AB, a company known for its commitment to developing innovative solutions for health-related challenges. His work has not only contributed to the scientific community but has also paved the way for new therapeutic options in gastrointestinal health.
Collaborations
Throughout his career, Conolly has collaborated with esteemed colleagues such as Wolfgang Kunze and John Bienenstock. These collaborations have further enhanced his research and have contributed to the advancement of knowledge in the field of gastrointestinal pain management.
Conclusion
Eamonn Conolly's innovative work in the selection of agents for gastrointestinal pain management highlights his dedication to improving health outcomes. His contributions through patents and collaborations reflect his commitment to advancing medical science.